The Emergence of Epidemic Dengue Fever and Dengue Hemorrhagic
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Vaccine to Prevent Human Papillomavirus
Resolution No. 6/20-1 ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT MENINGOCOCCAL DISEASE The purpose of this resolution is to update the resolution to reflect currently available meningococcal conjugate vaccines that can be used to prevent meningococcal disease attributable to serogroups A, C, W, and Y. VFC resolution 6/19-7 is repealed and replaced by the following: Meningococcal Conjugate Vaccines (MenACWY) Eligible Groups • Children aged 2 months through 10 years who are at increased risk for meningococcal disease attributable to serogroups A, C, W, and Y, including: o Children who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D) o Children taking a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris]) o Children who have anatomic or functional asplenia, including sickle cell disease o Children infected with human immunodeficiency virus (HIV) o Children traveling to or residing in countries in which meningococcal disease is hyperendemic or epidemic, particularly if contact with local population will be prolonged o Children identified to be at increased risk because of a meningococcal disease outbreak attributable to serogroups A, C, W, or Y • All children aged 11 through 18 years 1 Recommended Vaccination Schedule and Intervals The table below lists meningococcal conjugate vaccines currently available to prevent meningococcal disease attributable to serogroups A, C, W, and -
An Atlas of Potentially Water-Related Diseases in South Africa
AN ATLAS OF POTENTIALLY WATER-RELATED DISEASES IN SOUTH AFRICA Volume 2 Bibliography Report to the WATER RESEARCH COMMISSION by N Coetzee and D E Bourne Department of Community Health University of Cape Town Medical School WRC Report no. 584/2/96 ISBN 1 86845 245 X ISBN Set No 1 86845 246 8 1 CONTENTS VOLUME 2 BIBLIOGRAPHY 1 Introduction 2 2 Amoebiasis 3 3 Arthropod-borne viral diseases 7 4 Cholera 10 5 Diarrhoeal diseases in childhood 14 6 Viral hepatitis A and E 17 7 Leptospirosis 20 3 Pediculosis 22 9 Malaria 23 10 Poliomyelitis 29 11 Scabies 33 12 Schistosomiasis 35 13 Trachoma 39 14 Typhoid Fever 42 15 Intestinal helminthiasis 46 1. INTRODUCTION As many professionals involved in the management of water resources do not have a medical or public health background, it was thought that an explanatory bibliography of the major water related diseases in South Africa would be of use. Each section of the bibliography has (where appropriate) the following sections: 1. Aetiology 2. Transmission 3. Preventive and curative steps 4. South African data 5. References The MEDLINE data base of the national Library of Medicine, Washington DC, and the WATERLIT data base of the CSIR were searched. These were supplemented by South African journals and reports not appearing in the MEDLINE data base. 3 2. AMOEBIASIS 2.1. Aetiology The protozoan parasite Entamoeba histolytica which causes amoebiasis may exist as a hardy infective cyst or a more fragile and potentially pathogenic trophozoite (the "amoebic" form). Amoebiasis most commonly affects the colon and rectum as primary sitas of infection, with extraintestinal (most commonly liver abscesses), local or systemic, spread possible if not treated early. -
Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma
ORIGINAL CONTRIBUTION Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma Muluken Melese, MD, MPH Context Treatment recommendations assume that repeated mass antibiotic distri- Wondu Alemayehu, MD, MPH butions can control, but not eradicate or even locally eliminate, the ocular strains of Takele Lakew, MD, MPH chlamydia that cause trachoma. Elimination may be an important end point because of concern that infection will return to communities that have lost immunity to chla- Elizabeth Yi, MPH mydia after antibiotics are discontinued. Jenafir House, MPH, MSW Objective To determine whether biannual treatment can eliminate ocular chla- Jaya D. Chidambaram, MBBS mydial infection from preschool children and to compare results with the World Health Organization–recommended annual treatment. Zhaoxia Zhou, BA Design, Setting, and Participants A cluster-randomized clinical trial of biannual Vicky Cevallos, MT vs annual mass azithromycin administrations to all residents of 16 rural villages in the Kathryn Ray, MA Gurage Zone, Ethiopia, from March 2003 to April 2005. Kevin Cyrus Hong, BA Interventions At scheduled treatments, all individuals aged 1 year or older were Travis C. Porco, PhD, MPH offered a single dose of oral azithromycin either annually or biannually. Isabella Phan, MD Main Outcome Measure Village prevalence of ocular chlamydial infection and pres- ence of elimination at 24 months in preschool children determined by polymerase chain Ali Zaidi, MD reaction, correcting for baseline prevalence. Antibiotic treatments were performed af- Bruce D. Gaynor, MD ter sample collections. John P. Whitcher, MD, MPH Results Overall, 14 897 of 16 403 eligible individuals (90.8%) received their sched- uled treatment. -
Dengue in Florida (USA)
Insects 2014, 5, 991-1000; doi:10.3390/insects5040991 OPEN ACCESS insects ISSN 2075-4450 www.mdpi.com/journal/insects/ Article Dengue in Florida (USA) Jorge R. Rey Florida Medical Entomology Laboratory, University of Florida-IFAS, 200 9th Street S.E., Vero Beach, FL 32962, USA; E-Mail: [email protected]; Tel.: +1-772-778-7200 (ext. 136); Fax +1-772-7787205 External Editor: C. Roxanne Connelly Received: 30 October 2014; in revised form: 4 December 2014 / Accepted: 9 December 2014 / Published: 16 December 2014 Abstract: Florida (USA), particularly the southern portion of the State, is in a precarious situation concerning arboviral diseases. The geographic location, climate, lifestyle, and the volume of travel and commerce are all conducive to arbovirus transmission. During the last decades, imported dengue cases have been regularly recorded in Florida, and the recent re-emergence of dengue as a major public health concern in the Americas has been accompanied by a steady increase in the number of imported cases. In 2009, there were 28 cases of locally transmitted dengue in Key West, and in 2010, 65 cases were reported. Local transmission was also reported in Martin County in 2013 (29 cases), and isolated locally transmitted cases were also reported from other counties in the last five years. Dengue control and prevention in the future will require close cooperation between mosquito control and public health agencies, citizens, community and government agencies, and medical professionals to reduce populations of the vectors and to condition citizens and visitors to take personal protection measures that minimize bites by infected mosquitoes. -
Expert Meeting on Chikungunya Modelling
MEETING REPORT Expert meeting on chikungunya modelling Stockholm, April 2008 www.ecdc.europa.eu ECDC MEETING REPORT Expert meeting on chikungunya modelling Stockholm, April 2008 Stockholm, March 2009 © European Centre for Disease Prevention and Control, 2009 Reproduction is authorised, provided the source is acknowledged, subject to the following reservations: Figures 9 and 10 reproduced with the kind permission of the Journal of Medical Entomology, Entomological Society of America, 10001 Derekwood Lane, Suite 100, Lanham, MD 20706-4876, USA. MEETING REPORT Expert meeting on chikungunya modelling Table of contents Content...........................................................................................................................................................iii Summary: Research needs and data access ...................................................................................................... 1 Introduction .................................................................................................................................................... 2 Background..................................................................................................................................................... 3 Meeting objectives ........................................................................................................................................ 3 Presentations ................................................................................................................................................. -
Meeting of the Board of Scientific Counselors, Office of Infectious Diseases
MEETING OF THE BOARD OF SCIENTIFIC COUNSELORS, OFFICE OF INFECTIOUS DISEASES Centers for Disease Control and Prevention Tom Harkin Global Communications Center Atlanta, Georgia May 2–3, 2018 A one-and-a-half day, open public meeting of the Board of Scientific Counselors (BSC), Office of Infectious Diseases (OID), was held on May 2–3, 2018, at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. In addition to Board members and CDC staff, the meeting was attended by representatives of several public health partner organizations (appendix). The meeting included • Updates from OID, the Center for Global Health (CGH), and the National Centers for Immunization and Respiratory Diseases (NCIRD); HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); and Emerging and Zoonotic Infectious Diseases (NCEZID) • Updates from the BSC Infectious Disease Laboratory Working Group (IDLWG) and the new OID– National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR) Vector-borne Diseases Workgroup • Updates on activities to address antimicrobial resistance by Veterinary Services (VS), Animal and Plant Health Inspection Service, U.S. Department of Agriculture (USDA/APHIS) and CDC • Presentations and discussion about CDC efforts to address the opioid epidemic, train the next generation of public health workers, and advance the CDC High Containment Laboratory Initiative The meeting also included a conversation with CDC Director Robert Redfield. Opening Remarks BSC Chair Ruth Lynfield, State Epidemiologist and Medical Director, Minnesota Department of Health, called the meeting to order and was joined in welcoming participants and facilitating introductions by Sonja Rasmussen, CDC Deputy Director for Infectious Diseases, and Sarah Wiley, the BSC/OID Designated Federal Official. -
Waterborne Disease Risk Assessment Program 2019 Annual Report
New York City Department of Health & Mental Hygiene Bureau of Communicable Disease & New York City Department of Environmental Protection Bureau of Water Supply Waterborne Disease Risk Assessment Program 2019 Annual Report March 2020 Prepared in accordance with Section 8.1 of the NYSDOH 2017 NYC Filtration Avoidance Determination i TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................. i LIST OF TABLES ........................................................................................................................ iii LIST OF FIGURES ........................................................................................................................ iv LIST OF ACRONYMS ................................................................................................................... v ACKNOWLEDGMENTS .............................................................................................................. vi EXECUTIVE SUMMARY .......................................................................................................... vii 1. INTRODUCTION .................................................................................................................... 1 2. DISEASE SURVEILLANCE .................................................................................................. 1 2.1 Giardiasis .......................................................................................................................... 1 -
Recommended Adult Immunization Schedule
Recommended Adult Immunization Schedule UNITED STATES for ages 19 years or older 2021 Recommended by the Advisory Committee on Immunization Practices How to use the adult immunization schedule (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Determine recommended Assess need for additional Review vaccine types, Control and Prevention (www.cdc.gov), American College of Physicians 1 vaccinations by age 2 recommended vaccinations 3 frequencies, and intervals (www.acponline.org), American Academy of Family Physicians (www.aafp. (Table 1) by medical condition and and considerations for org), American College of Obstetricians and Gynecologists (www.acog.org), other indications (Table 2) special situations (Notes) American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org). Vaccines in the Adult Immunization Schedule* Report y Vaccines Abbreviations Trade names Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Haemophilus influenzae type b vaccine Hib ActHIB® y Clinically significant postvaccination reactions to the Vaccine Adverse Event Hiberix® Reporting System at www.vaers.hhs.gov or 800-822-7967 PedvaxHIB® Hepatitis A vaccine HepA Havrix® Injury claims Vaqta® All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix® Vaccine Injury Compensation Program. Information on how to file a vaccine injury Hepatitis B vaccine HepB Engerix-B® claim is available at www.hrsa.gov/vaccinecompensation. Recombivax HB® Heplisav-B® Questions or comments Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Human papillomavirus vaccine HPV Gardasil 9® Spanish, 8 a.m.–8 p.m. -
Medical Entomology in Brief
Medical Entomology in Brief Dr. Alfatih Saifudinn Aljafari Assistant professor of Parasitology College of Medicine- Al Jouf University Aim and objectives • Aim: – To bring attention to medical entomology as important biomedical science • Objective: – By the end of this presentation, audience could be able to: • Understand the scope of Medical Entomology • Know medically important arthropods • Understand the basic of pathogen transmission dynamic • Medical Entomology in Brief- Dr. Aljafari (CME- January 2019) In this presentation • Introduction • Classification of arthropods • Examples of medical and public health important species • Insect Ethology • Dynamic of disease transmission • Other application of entomology Medical Entomology in Brief- Dr. Aljafari (CME- January 2019) Definition • Entomology: – The branch of zoology concerned with the study of insects. • Medical Entomology: – Branch of Biomedical sciences concerned with “ArthrobodsIn the past the term "insect" was more vague, and historically the definition of entomology included the study of terrestrial animals in other arthropod groups or other phyla, such, as arachnids, myriapods, earthworms, land snails, and slugs. This wider meaning may still be encountered in informal use. • At some 1.3 million described species, insects account for more than two-thirds of all known organisms, date back some 400 million years, and have many kinds of interactions with humans and other forms of life on earth Medical Entomology in Brief- Dr. Aljafari (CME- January 2019) Arthropods and Human • Transmission of infectious agents • Allergy • Injury • Inflammation • Agricultural damage • Termites • Honey • Silk Medical Entomology in Brief- Dr. Aljafari (CME- January 2019) Phylum Arthropods • Hard exoskeleton, segmented bodies, jointed appendages • Nearly one million species identified so far, mostly insects • The exoskeleton, or cuticle, is composed of chitin. -
Immigration IZ– a Resource for Healthcare Providers
Immigration IZ– A resource for healthcare providers Vaccines required for immigration applications should be age appropriate. 1 For example, if the applicant is 35 2 years of age, then he or she is required to receive tetanus and diphtheria toxoids vaccine (Td) or tetanus and 3 diphtheria toxoids and acellular pertus- sis vaccine (Tdap), MMR, and varicella 4 (if no history of varicella disease). If 5 the applicant had previously received a dose or doses of a required vaccine but 6 had not completed the series, then the next required dose should be adminis- 7 tered according to standard ACIP rec- ommendations. 8 Can still recommend other vaccinations 9 based on risk factors, but they are not required. 10 11 Please note that HPV and Zoster are not a requirement for immigration 12 1. A fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older. 2. Tdap for all pregnant women. Adults with incomplete vaccination will receive remaining doses. Adults with unknown history of vaccination will receive 3 doses (Tdap for first dose; remaning doses and boosters with Td) 3. A fourth dose of polio is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. ministered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age 4. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella. Need at least one dose. -
Sexually Transmitted Infections Treatment Guidelines, 2021
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized -
Sexually Transmitted Diseases Treatment Guidelines, 2015
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory